Granted Patent
B2
US 12,566,485 · App. 18/420,548 · Granted Mar 3, 2026
Methods and articles of manufacture for hosting a safety critical application on an uncontrolled data processing device
Inventors:
Daniel M. Bernstein (El Granada, CA); Saeed Nekoomaram (San Mateo, CA); Mark K. Sloan (Redwood City, CA)
Assignee:
Abbott Diabetes Care Inc.
G06F1/3287G06F1/3203G06F8/61G06F9/5011G06F9/546G06F11/004G06F11/0721G06F11/0736G06F11/0751G06F11/079G06F11/3668G06F11/3688G06F11/3692G16H40/40G06F2201/865
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods and articles of manufacture for hosting a safety critical application on an uncontrolled data processing device are provided. Various checks and combinations of checks including installation, functional, host integrity, coexistence, interoperability, power management, and environment checks are performed at various times to determine if the safety critical application operates properly on the device. The operation of the SCA on the UDPD may be controlled accordingly.
Claims (24)
1 . A method for a safety critical application (SCA), installed on a mobile device in communication with a glucose on-demand device, to execute instructions stored on the mobile device to perform steps of the method, the steps comprising:
detecting, responsive to a predetermined event, a change in a software program currently installed on the mobile device, wherein the change to the software program comprises an update from a prior version of the software program to a current version of the software program, and wherein the detecting the change comprises determining that the current version of the software program does not match the prior version of the software program;
responsive to detecting the change to the software program, initiating a check to identify whether the SCA is incompatible with the current version of the software program, wherein the SCA is a glucose on-demand application, wherein the check is initiated when the SCA is in an active state;
responsive to identifying the SCA is incompatible with the current version of the software program, displaying, on the mobile device, an alert that the SCA is incompatible with the current version of the software program; and
responsive to identifying the SCA is incompatible with the current version of the software program, permitting the SCA, when in one of the active state or in an inactive state, to receive a glucose measurement from the glucose on-demand device.
2 . The method of claim 1 , wherein the predetermined event is when the SCA is opened.
3 . The method of claim 1 , wherein the predetermined event is when the SCA is closed.
4 . The method of claim 1 , wherein the predetermined event is when the mobile device is powered on.
5 . The method of claim 1 , wherein the predetermined event is a predetermined time.
6 . The method of claim 5 , wherein the predetermined time is while the SCA is running.
7 . The method of claim 5 , wherein the predetermined time is while the SCA is not running.
8 . The method of claim 1 , wherein the software program is a nonrelated program that does not work with the SCA but shares one or more resources with the SCA.
9 . The method of claim 8 , wherein the one or more resources comprises at least one of a software resource of the mobile device or a hardware resource of the mobile device.
10 . The method of claim 9 , wherein the hardware resource of the mobile device comprises a wireless communication device.
11 . The method of claim 1 , wherein initiating the check comprises determining whether a safety critical incompatibility exists between the SCA and the current version of the software program.
12 . The method of claim 1 , wherein the check is initiated while the current version of the software program is in an active state.
13 . The method of claim 1 , wherein the check is initiated while the current version of the software program is in a passive state.
14 . The method of claim 1 , wherein the SCA is configured to cause the mobile device to communicate with the glucose on-demand device.
15 . The method of claim 14 , wherein the SCA is configured to interoperate with software installed on the glucose on-demand device.
16 . The method of claim 1 , wherein the prior version of the software program is associated with a time when the SCA was previously determined to be compatible with the prior version of the software program.
17 . The method of claim 1 , wherein when the SCA is in the active state, the SCA is running in the foreground.
18 . The method of claim 1 , wherein the glucose measurement is transmitted to the mobile device via Bluetooth.
19 . The method of claim 1 , wherein the SCA is initiated to request data from the continuous glucose on demand device over a Bluetooth link.
20 . The method of claim 19 , further comprising: comparing data received in response to the request for data with reference communication data to determine whether the SCA communicates accurately over the Bluetooth link.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 25, 2024
From: BERNSTEIN, DANIEL M.; NEKOOMARAM, SAEED; SLOAN, MARK K.
To: ABBOTT DIABETES CARE INC.
Reel/Frame 066372/0276 →
Continuity (11)
Provisional Application
61359265
· Jun 28, 2010
Provisional Application
61240578
· Sep 8, 2009
References Cited (328)
US 3979657A
· Yorksie
· 1976
[cited by applicant]
US 5031616A
· Mann et al.
· 1991
[cited by applicant]
US 5394871A
· Sauer et al.
· 1995
[cited by applicant]
US 5506792A
· Adelson et al.
· 1996
[cited by applicant]
US 5572671A
· Eisenberg et al.
· 1996
[cited by applicant]
US 5754963A
· Nunneley et al.
· 1998
[cited by applicant]
US 6035421A
· Renno et al.
· 2000
[cited by applicant]
US 6081466A
· McClure et al.
· 2000
[cited by applicant]
US 6110228A
· Albright et al.
· 2000
[cited by applicant]
US 6128774A
· Necula et al.
· 2000
[cited by applicant]
US 6272674B1
· Holiday, Jr.
· 2001
[cited by applicant]
US 6285298B1
· Gordon
· 2001
[cited by applicant]
US 6421633B1
· Heinonen et al.
· 2002
[cited by applicant]
US 6490722B1
· Barton et al.
· 2002
[cited by applicant]
US 6546553B1
· Hunt
· 2003
[cited by applicant]
US 6558320B1
· Causey, III et al.
· 2003
[cited by applicant]
US 6604237B1
· Giammaria
· 2003
[cited by applicant]
US 6640334B1
· Rasmussen
· 2003
[cited by applicant]
US 6745385B1
· Lupu et al.
· 2004
[cited by applicant]
US 6807641B1
· Ishiguro et al.
· 2004
[cited by applicant]
US 6830180B2
· Walsh
· 2004
[cited by applicant]
US 7041468B2
· Drucker et al.
· 2006
[cited by applicant]
US 7152092B2
· Beams et al.
· 2006
[cited by applicant]
US 7191208B1
· Achtermann et al.
· 2007
[cited by applicant]
US 7251812B1
· Jhanwar et al.
· 2007
[cited by applicant]
US 7254608B2
· Yeager et al.
· 2007
[cited by applicant]
US 7266819B2
· Helgesen et al.
· 2007
[cited by applicant]
US 7308300B2
· Toews et al.
· 2007
[cited by applicant]
US 7322028B2
· Belovich
· 2008
[cited by applicant]
US 7334226B2
· Ramachandran et al.
· 2008
[cited by applicant]
US 7343364B2
· Bram et al.
· 2008
[cited by applicant]
US 7353509B2
· Sheehy
· 2008
[cited by applicant]
US 7467093B1
· Newton et al.
· 2008
[cited by applicant]
US 7509156B2
· Flanders
· 2009
[cited by applicant]
US 7542878B2
· Nanikashvili
· 2009
[cited by applicant]
US 7596784B2
· Abrams et al.
· 2009
[cited by applicant]
US 7682351B2
· Aoki
· 2010
[cited by applicant]
US 7689985B2
· Callender
· 2010
[cited by applicant]
US 7703093B2
· Fischer et al.
· 2010
[cited by applicant]
US 7867165B2
· Brown
· 2011
[cited by applicant]
US 7972267B2
· Brown
· 2011
[cited by applicant]
US 7996245B2
· Geidos et al.
· 2011
[cited by applicant]
US 8086665B1
· Soukup et al.
· 2011
[cited by applicant]
US 8103718B2
· O'Shea et al.
· 2012
[cited by applicant]
US 8184969B2
· Guthrie et al.
· 2012
[cited by applicant]
US 8204729B2
· Sher
· 2012
[cited by applicant]
US 8224669B2
· Peterka et al.
· 2012
[cited by applicant]
US 8234639B2
· Ramachandran et al.
· 2012
[cited by applicant]
US 8296043B2
· Mueller et al.
· 2012
[cited by applicant]
US 8296756B1
· Feeser et al.
· 2012
[cited by applicant]
US 8323189B2
· Tran
· 2012
[cited by applicant]
US 8370835B2
· Dittmer
· 2013
[cited by applicant]
US 8418172B2
· Addington et al.
· 2013
[cited by applicant]
US 8475739B2
· Holmes et al.
· 2013
[cited by applicant]
US 8533253B2
· McCoy
· 2013
[cited by applicant]
US 8554953B1
· Sorensen et al.
· 2013
[cited by applicant]
US 8555070B2
· Claus et al.
· 2013
[cited by applicant]
US 8562587B2
· Kovatchev
· 2013
[cited by applicant]
US 8566818B2
· Young
· 2013
[cited by applicant]
US 8576191B2
· Knott et al.
· 2013
[cited by applicant]
US 8578370B2
· Dai et al.
· 2013
[cited by applicant]
US 8601465B2
· Bernstein et al.
· 2013
[cited by applicant]
US 8615752B2
· Izard et al.
· 2013
[cited by applicant]
US 8621049B2
· Ebrom et al.
· 2013
[cited by applicant]
US 8628512B2
· Kochanek et al.
· 2014
[cited by applicant]
US 8726266B2
· Kiale
· 2014
[cited by applicant]
US 8732693B2
· Mitusya et al.
· 2014
[cited by applicant]
US 8813061B2
· Hoffman et al.
· 2014
[cited by applicant]
US 8862448B2
· Holmes et al.
· 2014
[cited by applicant]
US 8893120B2
· Pinsky et al.
· 2014
[cited by applicant]
US 8935691B2
· BenAyed
· 2015
[cited by applicant]
US 8954373B2
· Atlas
· 2015
[cited by applicant]
US 8978027B2
· Haemel et al.
· 2015
[cited by applicant]
US 9010477B2
· Saettel et al.
· 2015
[cited by applicant]
US 9015698B2
· Bernstein et al.
· 2015
[cited by applicant]
US 9015700B2
· Bernstein et al.
· 2015
[cited by applicant]
US 9058431B2
· Bernstein et al.
· 2015
[cited by applicant]
US 9122775B2
· Schunder
· 2015
[cited by applicant]
US 9124635B2
· Robinson et al.
· 2015
[cited by applicant]
US 9177153B1
· Perrig et al.
· 2015
[cited by applicant]
US 9218453B2
· Groll
· 2015
[cited by applicant]
US 9326709B2
· Budiman
· 2016
[cited by applicant]
US 9519333B2
· Bernstein et al.
· 2016
[cited by applicant]
US 9519334B2
· Bernstein et al.
· 2016
[cited by applicant]
US 9519335B2
· Bernstein et al.
· 2016
[cited by applicant]
US 9529414B2
· Bernstein et al.
· 2016
[cited by applicant]
US 9552052B2
· Bernstein et al.
· 2017
[cited by applicant]
US 9619013B2
· Bernstein et al.
· 2017
[cited by applicant]
US 9918635B2
· Bousamra
· 2018
[cited by examiner]
US 20020023852A1
· Mcivor et al.
· 2002
[cited by applicant]
US 20020045808A1
· Ford et al.
· 2002
[cited by applicant]
US 20050088147A1
· Svensson et al.
· 2005
[cited by applicant]
US 20050102669A1
· Marney et al.
· 2005
[cited by applicant]
US 20060178570A1
· Robinson et al.
· 2006
[cited by applicant]
US 20060229772A1
· McClary
· 2006
[cited by applicant]
US 20060230398A1
· Yokota
· 2006
[cited by applicant]
US 20070015983A1
· Werner et al.
· 2007
[cited by applicant]
US 20070214453A1
· Dive-Reclus
· 2007
[cited by applicant]
US 20070234337A1
· Suzuki et al.
· 2007
[cited by applicant]
US 20070266177A1
· Vismans et al.
· 2007
[cited by applicant]
US 20080014120A1
· Chiu et al.
· 2008
[cited by applicant]
US 20080127175A1
· Naranjo et al.
· 2008
[cited by applicant]
US 20080172665A1
· Mcilroy
· 2008
[cited by applicant]
US 20080183502A1
· Dicks et al.
· 2008
[cited by applicant]
US 20080234562A1
· Jina
· 2008
[cited by applicant]
US 20090120810A1
· Phan et al.
· 2009
[cited by applicant]
US 20090234465A1
· Karsten
· 2009
[cited by applicant]
US 20090235242A1
· Kawaguchi
· 2009
[cited by applicant]
US 20090249071A1
· De Atley et al.
· 2009
[cited by applicant]
US 20090292950A1
· Tsai
· 2009
[cited by applicant]
US 20090326759A1
· Hensel et al.
· 2009
[cited by applicant]
US 20100242034A1
· Rugh et al.
· 2010
[cited by applicant]
US 20110004084A1
· Feldman et al.
· 2011
[cited by applicant]
US 20120102546A1
· Jiang et al.
· 2012
[cited by applicant]
US 20140012118A1
· Mensinger
· 2014
[cited by examiner]
US 20220221927A1
· Bernstein et al.
· 2022
[cited by applicant]
CN 101151513A
· 2008
[cited by applicant]
CN 101369303A
· 2009
[cited by applicant]
DE 1008003531
· 2009
[cited by applicant]
EP 1224543B1
· 2009
[cited by applicant]
EP 4087195B1
· 2023
[cited by applicant]
WO WO2006043143A2
· 2006
[cited by applicant]
WO WO2006050492A2
· 2006
[cited by applicant]
WO WO2010005908A1
· 2010
[cited by applicant]
WO WO20100091102A1
· 2010
[cited by applicant]
WO WO2010141922A1
· 2010
[cited by examiner]
Dolan, Brian, “Inteview: Lifescan on iPhone 3.0,” MobiHealthNews, Mar. 18, 2009; 14 pages; available at: https://www.mobihealthnews.com/973/interview-lifescan-on-iphone-30.
[cited by applicant]
“LifeScan and Apple Partner Up for iphone OS 3.0 (A Revolution in Diabetes),” video posted by blewmymind.com, Apr. 13, 2009; 3 pages; available at: https://www.youtube.com/watch?v=HyiSxfdytoA.
[cited by applicant]
Sarasohn-Kahn, Jane, M.A., M.H.S.A., “How Smartphones Are Changing Health Care for Consumers and Providers,” California HealthCare Foundation, Oakland, CA, Apr. 2010; 23 pages.
[cited by applicant]
Exhibit CP-2, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022, Bailey, M.D., Sparacino, Giovanni et al., “Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series,” …
[cited by applicant]
Exhibit CP-3, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022, Bailey, M.D., Sparacino, Giovanni et al., “Glucose Concentration can be Predicted Ahead in Time From Continuous Glucose Monitoring Sensor Time-Series,” …
[cited by applicant]
Exhibit CP-4, Expert Report of Dr. Cesar C. Palerm, Sep. 20, 2022, “Animas® Vibe TM, the First Integrated Offering from Animas Corporation and Dexcom, Inc, Receives European CE Mark Approval”, Products & Operating Compa…
[cited by applicant]
Exhibit CP-6, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022, Bailey, T.S. et al., “Reduction in Hemoglobin A1c with Real-Time Continuous Glucose Monitoring: Results from a 12-Week Observational Study” Diabe…
[cited by applicant]
Exhibit CP-7, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022, Garg, S. et al., “Improvement in Glycemic Excursions with a Transcutaneous, Real-Time Continuous Glucose Sensor”, Diabetes Care, Jan. 2006, 29(12…
[cited by applicant]
Exhibit CP-8, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022, Garg, S. et al., Relationship of Fasting and Hourly Blood Glucose Levels to HbAlc Values, Diabetes Care, Dec. 2006, 6(12):2644-2649.
[cited by applicant]
Exhibit CP-9, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022, “Welcome to Your FreeStyle Libre System,” In-Service Guide, FreeStyle Libre, Flash Glucose Monitoring System, Abbott, 2017, 22 pages.
[cited by applicant]
Exhibit CP-10, Second Expert Report of Dr. Cesar C. Palerm, Oct. 21, 2022, “Standards of Medical Care in Diabetes-2009” Position Statement, American Diabetes Association, 2009, Diabetes Care, 32(1):S13-S61.
[cited by applicant]
Exhibit VS-2, Expert Report of Dr. Vlad Stirbu, 2022, Attaching multiple articles and press releases relating to software platforms and applications, 2008-2022; 176 pages.
[cited by applicant]
Exhibit VS-3 to the Expert Report of Dr. Vlad Stirbu, “Annex A to the Statement of Grounds,” 2022; 2 pages.
[cited by applicant]
Exhibit VS-5, Expert Report of Dr. Vlad Stirbu, 2022, “Wayback Machine screen captures for Nokia N800 Internet Tablet,” http://www.nokia.co.uk/, dated 2007-2008, 8 pages.
[cited by applicant]
Entra Health Introduce World's First FDA Cleared Bluetooth Blood Glucose Meter, Diabetic Insights Newsletter, Winter Ed., 2009; 4 pages.
[cited by applicant]
Gluco Tel Flyer, Mar. 12, 2008; 1 page.
[cited by applicant]
GlucoTel User Manual, May 30, 2008; 24 pages.
[cited by applicant]
MyGlucoHealth Newsletter, World's Smartest Mobile Diabetes Care Solution brochure, Extra Health Systems, Oct. 22, 2009; 4 pages.
[cited by applicant]
MyGlucoHealth Operation Manual, 2009; 23 pages.
[cited by applicant]
GlucoRx Presentation, 2010; 22 pages.
[cited by applicant]
GlucoRx HCT Connect Owners Manual, Jun. 2016; 40 pages.
[cited by applicant]
Holtz et al., Diabetes Management via Mobile Phones, Telemedicine and e-Health, vol. 18, No. 3; Apr. 2012; pp. 175-184.
[cited by applicant]
Mobile Information Device Profile for Java TM 2 Micro Edition, v. 2.1, Sun Microsystems, Inc. and Motorola, Inc., May 26, 2006; 92 pages.—Exhibit D02 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Dolan, Brian, My GlucoHealth Diabetic Monitoring Service Launches in Australia, MobiHealth News, Dec. 17, 2009; 19 pages.—Exhibit D10 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Bruce, Sarah, Nokia Supports Diabetes App., Digital Health, Apr. 9, 2010; 5 pages.—Exhibit D11 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Photo Release—MyGlucoHealth Diabetes App Now Available on Ovi Store by Nokia, Entra Health, Apr. 7, 2010; 2 pages.—Exhibit D12 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Heath, Craig, Symbian OS Platform Security excerpts, John Wiley & Sons, Ltd., 2006; 10 pages.—Exhibit D15 in the Opposition to European Patent No. 4087195.
[cited by applicant]
DexComTM STSTM Continuous Glucose Monitoring System, User's Guide, 2006; 57 pages.—Exhibit D19 in the Opposition to European Patent No. 4087195.—pages cut off.
[cited by applicant]
Apple Stellt iPhone 4 Vor, Apple Press Release dated Jun. 7, 2010; 10 pages.—Exhibit HE4 in the Opposition to European Patent No. 4087195.—German Language document with attached machine translation.
[cited by applicant]
Herrman, John, There are Now Over 50,000 Android Apps, Gizmodo, Apr. 24, 2010; 4 pages.—Exhibit HE5 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Extract from the Register of European Patents regarding European Patent No. 4087195, Exhibit TW2 in the United Patent Court, downloaded Sep. 9, 2023; 3 pages.
[cited by applicant]
Comparison of Claim 1 of EP2476223 and Claim 1 of EP4087195,
[cited by applicant]
Feature Analysis for European Patent No. 4087195,
[cited by applicant]
DexCom, Inc. webpage describing the Dexcom rtCGM system for continuous glucose monitoring, accessed Sep. 20, 2023,
[cited by applicant]
DexCom Inc.'s Counterclaim for Revocation in the Unified Patent Court, Local Division, Munich, regarding European Patent No. 4087195, Feb. 26, 2024; 77 pages.
[cited by applicant]
Verdict in
[cited by applicant]
Partial English-language translation of Verdict in
[cited by applicant]
Abbott Response to Rule 58 Communication to remedy deficiencies regarding European Patent Application No. 22165695.2, attaching amended claims, Annex D5 in the Unified Patent Court regarding European Patent No. EP407072…
[cited by applicant]
Communication from the European Patent Office to Abbott mailing European Search Report for European Patent Application No. 22165695.2, Annex D6 in the Unified Patent Court regarding European Patent No. EP4070727, dated …
[cited by applicant]
Abbott Response to Rule 71(3) Communication to remedy deficiencies regarding European Patent Application No. 22165695.2, attaching amended claims, and description, Annex D9 in the Unified Patent Court regarding European…
[cited by applicant]
Opposition to EP4070727 (European Patent Application No. 22165695.2) filed by Dexcom, Inc., against Abbott Diabetes Care, Inc. in the European Patent Office, Annex D10 in the Unified Patent Court regarding European Pate…
[cited by applicant]
Case summaries relating to novelty in the Enlarged Board of Appeal—Section 5.2.8—Non-technical distinguishing features, Annex D20 in the Unified Patent Court regarding European Patent No. EP4070727, no date; 1 page.
[cited by applicant]
Decision of the Enlarged Board of Apppeal in
[cited by applicant]
Excerpt from Guidelines for Examination in the EPO, Part G—Chapter II-22; Mar. 2024; Annex D22 in the Opposition to European Patent No. EP4070727; 6 pages.
[cited by applicant]
Decision of the Technical Board of Appeal in
[cited by applicant]
Decision of the Technical Board of Appeal in Appeal of The Cleveland Clinic Foundation regarding European Patent Application No. 05794215.3, Case No. T 1802/13; Annex D24 in the Unified Patent Court regarding European P…
[cited by applicant]
Approved
[cited by applicant]
Decision of the Technical Board of Appeal in Appeal of Duns Licensing Associates, L.P. regarding European Patent Application No. 94912949.8, Case No. T 154/04; Annex D26 in the Unified Patent Court regarding European Pa…
[cited by applicant]
Decision of the Enlarged Board of Appeal in Appeal of Interlocutory Decision by Bentley Systems (UK) Limited, Case No. G 0001/19; Annex D27 in the Unified Patent Court regarding European Patent No. EP4070727, dated Mar.…
[cited by applicant]
Approved Judgment in
[cited by applicant]
Excerpt from Case Law of the Board of Appeal of the European Patent Office, 10th Edition, Annex D36 in the Unified Patent Court regarding European Patent No. EP4070727, 2022; 15 pages.
[cited by applicant]
Partial redacted brief, Exhibit QE4 in the Unified Patent Court regarding European Patent No. 4087195, no date; 28 pages.
[cited by applicant]
Grounds of Opposition for European Patent No. 2476233 B1, in the name of Abbott Diabetes Care, Inc., filed in the European Patent Office by DexCom Int. Ltd. in
[cited by applicant]
Request for Accelerated Proceedings in Grounds of Opposition for European Patent No. 2476233 B1, in the name of Abbott Diabetes Care, Inc., filed in European Patent Office by DexCom Int. Ltd. in
[cited by applicant]
Reply to Oppositions in Opposition for European Patent No. 2476223 B1, in the name of Abbott Diabetes Care, Inc., filed in European Patent Office by DexCom Int. Ltd. in
[cited by applicant]
Summons to Attend Oral Proceedings in Opposition for European Patent No. 2476223 B1, in the name of Abbott Diabetes Care, Inc., filed in European Patent Office, Aug. 11, 2022; 14 pages.
[cited by applicant]
Abbott Diabetes Care, Inc.'s Written Submission in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Jan. 23, 2023; 15 pages.
[cited by applicant]
Dexcom Inc.'s Written Submission in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Jan. 23, 2023; 18 pages.
[cited by applicant]
Minutes of Oral Proceedings in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Apr. 5, 2023; 11 pages.
[cited by applicant]
Summons to Oral Proceedings in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, May 8, 2023; 8 pages.
[cited by applicant]
Judgment of the Karlsruhe Higher Regional Court—6 U 146-22 relating to appeal of patent infringement of EP2476223 from Stihler Regional Court, dated Jun. 28, 2023 (with attached partial English-language translation); 12…
[cited by applicant]
Written Submissions of Abbott Diabetes Care Inc. in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Oct. 12, 2023; 2 pages.
[cited by applicant]
Written Submissions of Dexcom Inc. in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Oct. 12, 2023; 41 pages.
[cited by applicant]
Consolidated List of Cited Documents in in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, No Date, 2 pages.
[cited by applicant]
Submission of Abbott Diabetes Care Inc. in Opposition Proceedings on European Patent No. 2,476,233; European Patent Office, Dec. 4, 2023; 9 pages.
[cited by applicant]
BodyTel to Launch Gloco Tel System in August, Press Release, https://www.globenewswire.com, Jul. 8, 2008; 4 pages. Exhibit D24 in the Opposition to European Patent No. 4087195B1.
[cited by applicant]
Application Signing, Android Open Source Project, https://source.android.com; accessed Sep. 1, 2024; 5 pages. Exhibit D25 in the Opposition to European Patent No. 4087195B1.
[cited by applicant]
Dexcom Rejoinder to the Reply to the Defence to the Counterclaim and Reply to the Defence to the Application to Amend, Unified Patent Court, Action No. 584295/2023, Jul. 26, 2024; 34 pages.
[cited by applicant]
Transcript of Proceedings, Day 2 in Claim No. HP-2021-000025/HP-2021-000026, In the High Court of Justice Business and Property Courts, Intellectual Property List, Chancery Division, Dec. 2, 2022; 77 pages.
[cited by applicant]
Transcript of Proceedings, Day 4 in Claim No. HP-2021-000025/HP-2021-000026, In the High Court of Justice Business and Property Courts, Intellectual Property List, Chancery Division, Dec. 6, 2022; 77 pages.
[cited by applicant]
Opposition Appeal to European Patent No. 2476223,
[cited by applicant]
Supplemental Submission in Opposition Appeal to European Patent No. 2476223,
[cited by applicant]
Further Submission in Opposition Appeal to European Patent No. 4087195,
[cited by applicant]
Consolidated List of Exhibits in Opposition Appeal to European Patent No. 4087195,
[cited by applicant]
Arai et al. (1994) “A portable transcutaneous blood glucose monitoring system using non-invasive collection of suction effusion fluid from skin” IEEE, pp. 812-813.
[cited by applicant]
Burg et al., “Software Deployment in a Dynamic Cloud: From Device to Service Orientation in a Hospital Environment”, IEEE, pp. 61-66 (2009).
[cited by applicant]
Candea et al., “Automated Software Testing as a Service”, ACM, pp. 155-160 (2010).
[cited by applicant]
Chaudet et al. (2005) “Optimal positioning of active and passive monitoring devices” Proceedings of the 2005 ACM conference on Emerging network experiment and technology, ACM, pp. 71-82.
[cited by applicant]
Chu and Ganz, WISTA: A Wireless Telemedicine System for Disaster Patient Care, Mobile Netw Appl, 12:201-214 (2012).
[cited by applicant]
Colmenar et al. (2016) “Predicting Glycemia in Diabetic Patients By Evolutionary Computation and Continuous Glucose Monitoring” Proceedings of the 2016 on Genetic and Evolutionary Computation Conference Companion, ACM, …
[cited by applicant]
Communication Pursuant to Article 94(3) EPC dated Jan. 22, 2018, regarding European Patent Application No. 10815970.8.
[cited by applicant]
Danholt and Booker (2005) “The implementation process of a diabetes EPR” Proceedings of the 4th decennial conference on Critical computing: between sense and sensibility, pp. 187-190.
[cited by applicant]
Dasman et al. (2011) “Diabetes care in the age of Informatics: Kuwait-Scotland Health Innovation Network” ACM, pp. 1-7.
[cited by applicant]
Drasanna et al., “Decision Support System for Detection of Diabetic Retinopathy Using Smartphones”, ACM-ICST pp. 176-179 (2013).
[cited by applicant]
Extended European Search Report directed to related European Patent Application No. 21167794.3, mailed Nov. 8, 2021; 9 pages.
[cited by applicant]
Extended European Search Report directed to related European Patent Application No. 21194269.3, mailed Dec. 22, 2021; 10 pages.
[cited by applicant]
Huang and Madey, “Autonomic Web-based Simulation”, IEEE, Proceedings of the 38th Annual Simulation Symposium, pp. 1-8 (2005).
[cited by applicant]
Javeen Kumar et al. (2013) Real lime glucose monitoring system based on enzymatic nanosensor Advanced Nanomaterials and Emerging Engineering Technologies (ICANMEET), 2013 International Conference on. IEEE, pp. 379-382.
[cited by applicant]
Kumar (2014) “Insulin Management System for Diabetic Patients” ACM, pp. 102-107.
[cited by applicant]
Medeiros (2015) “Safely evolving configurable systems” Companion Proceedings of the 2015 ACM SIGPLAN International Conference on Systems, Programming, Languages and Applications: Software for Humanity, ACM, pp. 85-86.
[cited by applicant]
Medikonda et al. (2009) “A Framework for Software Safety in Safely-Critical Systems” SIGSOFT Software Engineering Notes 34(2):1-9.
[cited by applicant]
Milewski et al. (2010) “Gathering Requirements for a Personal Health Management System” ACM, pp. 415-416.
[cited by applicant]
Mulvaney et al., “Monitoring Heart Disease and Diabetes with Mobile Internet Communications”, International Journal ofTelemedicine and Applications, vol. 2012, Article ID 195970, pp. 1-12 (2012).
[cited by applicant]
Nivas, “Test Harness and Script Design Principles for Automated Testing of Non-GUI or Web Based Applications”, ACM, pp. 30-37 (2011).
[cited by applicant]
Notification of the First Chinese Office Action dated Jun. 26, 2017, regarding Chinese Patent Application No. 201510263994.0 with English Translation.
[cited by applicant]
Pai et al. (2015) “A photoacoustics based continuous non-invasive blood glucose monitoring system” Medical Measurements and Applications (MeMeA), 2015 IEEE International Symposium on. IEEE, pp. 1-6.
[cited by applicant]
Pava et al., “A Self-Configuring Test Harness for Web Applications”, ACM pp. 1-6 (2009).
[cited by applicant]
Preuveneers and Berbers (2008) “Mobile phones assisting with health self-care: a diabetes case study” Proceedings of the 10th international conference on Human computer interaction with mobile devices and services, ACM,…
[cited by applicant]
Santos et al., “SiSPED 2.0: An Extension of a System to Monitor Diabetic Patients”, ACMpp.11-18 (2012).
[cited by applicant]
Subramanian et al., “Dynamic Software Updates: A VM-centric Approach”, PLD1'09, Dublin, 1E, pp. 1-12 (2009).
[cited by applicant]
Sutton et al. (2011) “An Ontology of Diabetes Self Management” ACM, pp. 83-86.
[cited by applicant]
Visser et al. (2014) “Point-of-Care Testing for Diabetes Patients: Investigating Diabetes Management by Older Adults” ACM, pp. 1645-1650.
[cited by applicant]
Vo et al., “Formal Verification of Practical MPI Programs”, ACM, pp. 261-269 (2009).
[cited by applicant]
Walters, R. A. et al., “Software Safety Techniques for Implantable Medical Devices,” Proceedings of the Annual International Conference of the Engineering in Medicine and Biology Society. Paris, Oct. 29-Nov. 1, 1992; [P…
[cited by applicant]
Ye et al. (2011) “Human identification based on ECG signals from wearable health monitoring devices” Proceedings of the 4th International Symposium on Applied Sciences in Biomedical and Communication Technologies, ACM, …
[cited by applicant]
Claimants' Amended Reply and Defence to Counterclaim in Claim No. HP-2021-000025, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Defendants' Amended Defence and Counterclaim in Claim No. HP-2021-000025, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Defendants' Amended Grounds of Invalidity in Claim No. HP-2021-000025, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Claimants' Amended Grounds of Invalidity in Claim No. HP-2021-000026, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Abbott's Opening Skeleton Argument,
[cited by applicant]
Opening Written Submissions of Dexcom,
[cited by applicant]
Expert Report of Cesar C. Palerm,
[cited by applicant]
Redacted Second Expert Report of
[cited by applicant]
Redacted Third Expert Report of
[cited by applicant]
Claimants' Amended Reply and Defence to Counterclaim in Claim No. HP-2021-000026, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Application Notice (as proposed to be amended for EP3782539 B1) in Claim No. HP-2021-000026, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Statement of Grounds (as proposed to be amended for EP2476223B1) in Claim No. HP-2021-000025, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Annex A to Statement of Grounds, 223—Patent—Redline version of conditional amendment,
[cited by applicant]
Dexcom's Grounds of Opposition Amendment for European Patent No. 2476233 B1, in the name of Abbott Diabetes Care, Inc., filed in the European Patent Office by DexCom Int. Ltd. in
[cited by applicant]
Letter from the Comptroller (as proposed to be amended 223) in Claim No. HP-2021-000025, In The High Court of Justice, Business and Property Courts of England and Wales,
[cited by applicant]
Dexcom Inc.'s Closing Skeleton Argument,
[cited by applicant]
Dexcom Inc.'s Closing Skeleton Argument, Introduction,
[cited by applicant]
Abbott Diabetes Care, Inc.'s Closing Skeleton Argument, General and Witnesses,
[cited by applicant]
Abbott Diabetes Care, Inc.'s Closing Skeleton Argument, EP233,
[cited by applicant]
Abbott Diabetes Care, Inc et al.'s Re-Amended Reply and Defence to Counterclaim,
[cited by applicant]
Dexcom Inc et al.'s Re-Re-Re-Amended Reply and Defence to Counterclaim,
[cited by applicant]
Dexcom Inc et al.'s Re-Re-Re-Re Amended Reply and Defence to Counterclaim,
[cited by applicant]
Results of Oral Proceedings for European Patent No. 2,476,223; European Patent Office; Dec. 12, 2023; 6 pages.
[cited by applicant]
Extended European Search Report for European Patent Application No. 23201090.0 filed by Abbott Diabetes Care, Inc.; European Patent Office; Dec. 15, 2023; 10 pages.
[cited by applicant]
Interlocutory Decision in Opposition Proceedings on European Patent No. 2,476,223; European Patent Office; Feb. 1, 2024; 1 page.
[cited by applicant]
DexCom Appeal of the Decision in Opposition Proceedings on European Patent No. 2,476,233, DexCom Int. Ltd. in
[cited by applicant]
Notice of Commencement of Proceedings Before the Board of Appeal for Decision in Opposition Proceedings for European Patent No. 2,476,233, in
[cited by applicant]
Annex 1, Facts and Arguments in the Opposition to European Patent No. 4087195, dated May 23, 2024;
[cited by applicant]
Communication of a Notice of Opposition to European Patent No. 4087195, dated May 29, 2024;
[cited by applicant]
Interlocutory Decision Minutes in Opposition Proceedings regarding European Patent No. 2,476,223; European Patent Office; Feb. 5, 2024; 76 pages.
[cited by applicant]
DexCom Inc. Notice of Opposition to European Patent No. 4087195, dated Aug. 23, 2023;
[cited by applicant]
Annex 1, Facts and Arguments in the Opposition to European Patent No. 4087195, dated Feb. 26, 2024;
[cited by applicant]
Letter from Abbott Diabetes Care, Inc. regarding filing of divisional patent application from European Patent Application No. 21167794.3 with claim basis, dated Jun. 24, 2022, Exhibit HE2 in the Opposition to European P…
[cited by applicant]
Approved Judgment in
[cited by applicant]
Specification of the Bluetooth System, Master Table of Contents & Compliance Requirements, version 4.0, Jun. 30, 2010; Pts. 1-4; 2302 pages.
[cited by applicant]
Martinez-Sarriegui et al., Mobile Telemedicine for Diabetes Care, Bioengineering and Telemedicine Group, Technical University of Madrid, Jun. 2008; 20 pages, attaching www.researchgate.net webpage showing download sourc…
[cited by applicant]
Excerpts from the Proprietors' Defence to the Counterclaim for Revocation, dated Apr. 26, 2024; 4 pages. Exhibit D36 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Quick Start Guide, Gluco Tel Screenshots, dated 2006-2009; 2 pages. Exhibit D37 in the Opposition to European Patent No. 4087195.
[cited by applicant]
GlucoTel First Steps Part 2 YouTube Screenshot, dated Feb. 25, 2009; 1 page. Exhibit D38 in the Opposition to European Patent No. 4087195.
[cited by applicant]
MyGlucoHealth Wireless Meter—Screenshot, 2009; 1 page. Exhibit D39 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Myglucohealth.mov—Screenshot, dated Dec. 8, 2008; 1 page. Exhibit D40 in the Opposition to European Patent No. 4087195.
[cited by applicant]
DexComs STS User Manual site—screenshots, dated Oct.-Dec. 2007; 2 pages. Exhibit D41 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Java 2 Micro Edition Basics, Chapter 1, dated Oct. 30, 2001; 11 pages. Exhibit D42 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Rukzio, Enrico, et al., MobileHCI05, Tutorial: Development of Interactive Applications for Mobile Devices, 7th International Conference on Human Computer Interaction with Mobile Devices and Services, 2005; 24 pages. Exh…
[cited by applicant]
Debbabi, Mourad et al., Java for Mobile Devices: A Security Study, dated Jan. 2006; 10 pages. Exhibit D44 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Mobile Information Device Profile for Java TM 2 Micro Edition, v. 2.0, Sun Microsystems, Inc. and Motorola, Inc., Nov. 5, 2002; 74 pages. Exhibit D45 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Java MIDP 2.0 Change Log, downloaded Sep. 30, 2024; 8 pages. Exhibit D46 in the Opposition to European Patent No. 4087195.
[cited by applicant]
Abbott Diabetes Care, Inc.'s Annex to Reply to Grounds of Appeal regarding the Opposition to European Patent No. 2476223, dated Oct. 11, 2024; 68 pages.
[cited by applicant]
Abbott Diabetes Care, Inc.'s Appeal Requests regarding the Opposition to European Patent No. 2476223, dated Oct. 11, 2024; 283 pages.
[cited by applicant]
Abbott Diabetes Care, Inc.'s Reply to Appeal regarding the Opposition to European Patent No. 2476223, dated Oct. 11, 2024; 81 pages.
[cited by applicant]
Dexcom's Further Submissions regarding the Opposition to European Patent No. 4087195, dated Oct. 16, 2024; 82 pages.
[cited by applicant]
Consolidated List of Exhibits DI-D47 regarding the Opposition to European Patent No. 4087195, dated Oct. 16, 2024; 2 pages.
[cited by applicant]
Summons to Attend Oral Proceedings regarding the Opposition to European Patent No. 4087195, Dec. 3, 2024; 17 pages.
[cited by applicant]
Abbott Reply to Notices of Opposition to European Patent No. 4087195,
[cited by applicant]
Cited By (1)